"Dermatologicals in Belgium" Published

In spite of a continuous lack of innovation in the category, players were rather satisfied by the performance of dermatologicals in 2014 and 2015. Belgian consumers seem to want to take greater care of their bodies and, due to continuous information campaigns, an increasing number of potential consumers are aware of issues related to their skin, hair and nails. In 2015, this resulted in robust growth in categories such as topical antifungals, topical allergy remedies/antihistamines and cold sore treatments. The latter recovered from its weak performance in 2014 thanks to the better fate of generics and the offensive of Lipactin from Louis Widmer during the winter 2015.

Competitive Landscape

The competitive landscape in 2014 and 2015 in particular witnessed disparate performances, with sluggish growth or even declines for mainstream players contrasting with the impressive growth of some more modest operators. For instance, after a relatively good performance in 2014, the leader Janssen-Cilag (GBO: Johnson & Johnson) did not manage to forge ahead in 2015. Holding a 15% value share, the Belgian NBO benefited from the strength of its Daktarin umbrella brand in antifungals and Nizoral in medicated shampoos. However, after its recovery in topical antifungals in 2014, Daktarin remained at a standstill in the first half of 2015, while Daktozin recorded a decline in sales in 2015.

Full Report Details at
- http://www.fastmr.com/prod/1082163_dermatologicals_belgium.aspx?afid=302

Industry Prospects

Two consecutive years of robust increases tended to reassure players, which became more optimistic about the potential for dermatologicals, although continuing to complain of constraining factors. A fragile recovery in consumer purchasing power and the limited marketing resources of some manufacturers are expected to discourage innovation in the short term. The small size of many categories will also deter some manufacturers from investing in new product development. As many products in dermatologicals are not considered crucial by consumers, or face competition from reimbursed Rx products, this hampers self-medication in the category. When promoting their offers, medical representatives tend to favour sales of Rx products to dermatologists over OTC products to chemists/pharmacies. The strong Rx orientation of many products will continue to be a threat to dermatologicals as, at the first sign of skin problems, sufferers typically visit a general practitioner and/or specialist, who will often prescribe an Rx treatment, which is considered more efficient and is usually reimbursable.

Report Overview

Discover the latest market trends and uncover sources of future market growth for the Medicated Skin Care industry in Belgium with research from Euromonitor's team of in-country analysts.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Dermatologicals in the United Arab Emirates
- Dermatologicals in Thailand
- Dermatologicals in Algeria
- Dermatologicals in Denmark
- Dermatologicals in Morocco